Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review
Ann Oncol
.
2021 Feb;32(2):282-283.
doi: 10.1016/j.annonc.2020.12.001.
Epub 2020 Dec 9.
Authors
S N Deftereos
1
,
D Georgonikou
2
Affiliations
1
Neurology Department, Private Practice, Athens, Greece. Electronic address: deftereo@gmail.com.
2
Neurology Department, Private Practice, Athens, Greece.
PMID:
33309745
DOI:
10.1016/j.annonc.2020.12.001
No abstract available
Publication types
Letter
Systematic Review
MeSH terms
Humans
Immune Checkpoint Inhibitors*
Rituximab / adverse effects
Substances
Immune Checkpoint Inhibitors
Rituximab